Cetera Advisors LLC Aurinia Pharmaceuticals Inc. Transaction History

Cetera Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$4.93 - $9.31 $47,066 - $88,882	9,547 Added 18.87%	60,139 $301,000
Q4 2023 Feb 13, 2024	BUY	$7.13 - $9.49 $17,112 - $22,776	2,400 Added 4.98%	50,592 $454,000
Q3 2023 Nov 14, 2023	BUY	$7.77 - $12.27 $21,973 - $34,699	2,828 Added 6.23%	48,192 $374,000
Q2 2023 Aug 09, 2023	BUY	$8.96 - $11.69 $9,542 - $12,449	1,065 Added 2.4%	45,364 $439,000
Q1 2023 May 15, 2023	BUY	$5.94 - $11.27 $53,454 - $101,418	8,999 Added 25.49%	44,299 $485,000
Q3 2022 Nov 10, 2022	BUY	$6.66 - $12.39 $1,998 - $3,717	300 Added 0.86%	35,300 $265,000
Q2 2022 Aug 11, 2022	BUY	$8.95 - $12.8 $29,096 - $41,612	3,251 Added 10.24%	35,000 $352,000
Q1 2022 May 12, 2022	BUY	$10.05 - $22.48 $45,727 - $102,284	4,550 Added 16.73%	31,749 $393,000
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $19,006 - $35,362	-1,069 Reduced 3.78%	27,199 $622,000
Q3 2021 Nov 16, 2021	BUY	$10.93 - $23.55 $176,661 - $380,638	16,163 Added 133.52%	28,268 $626,000
Q2 2021 Aug 13, 2021	BUY	$10.0 - $14.52 $121,050 - $175,764	12,105 New	12,105 $157,000

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Cetera Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisors LLC with notifications on news.